Potassium (3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate
|
- $1021 - $1437
- Product name: Potassium (3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate
- CAS: 1402242-84-5
- MF: C7H11BF3KN2
- MW: 230.0801496
- EINECS:
- MDL Number:MFCD25948967
- Synonyms:Potassium (3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate
4 prices
Selected condition：
Brand
- AK Scientific
- Chemenu
- Crysdot
- Matrix Scientific
Package
- 500mg
- 1g
- ManufacturerAK Scientific
- Product number4157AD
- Product descriptionPotassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate
- Packaging500mg
- Price$1437
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM208915
- Product descriptionPotassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate 95%
- Packaging1g
- Price$1021
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11264238
- Product descriptionPotassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate 95+%
- Packaging1g
- Price$1084
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number101506
- Product descriptionPotassium (3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate >95%
- Packaging500mg
- Price$1028
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 4157AD | Potassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate | 500mg | $1437 | 2021-12-16 | Buy |
| Chemenu | CM208915 | Potassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate 95% | 1g | $1021 | 2021-12-16 | Buy |
| Crysdot | CD11264238 | Potassium(3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate 95+% | 1g | $1084 | 2021-12-16 | Buy |
| Matrix Scientific | 101506 | Potassium (3-(tert-butyl)-1H-pyrazol-5-yl)trifluoroborate >95% | 500mg | $1028 | 2021-12-16 | Buy |
Properties
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||
| Precautionary statements: |
|